FENNELL GEORGE 4

What Happened

• George Fennell, Executive Vice President of IDEXX Laboratories (IDXX), exercised stock options and sold most of the resulting shares. He exercised 1,476 options on 2026-02-09 and 11,345 options on 2026-02-10 at an exercise price of $67.85 per share (total exercise cost $869,905).
• On 2026-02-10 he sold 11,345 shares in multiple open-market trades at prices ranging roughly $642.60 to $650.32 per share for aggregate gross proceeds of about $7,336,993. After subtracting the exercise cost, the approximate pre-tax spread was ~$6,467,088.

Key Details

• Transaction dates: exercises on 2026-02-09 and 2026-02-10; open-market sales on 2026-02-10.
• Exercise price: $67.85 per share (total paid ≈ $869,905). Sale price range: ≈ $642.60–$650.32; total sale proceeds ≈ $7.34M.
• Shares exercised: 12,821 (1,476 + 11,345). Shares sold: 11,345.
• Shares owned after the transactions: not specified in the Form 4 filing.
• Notable footnotes: F1–F7 give weighted-average price ranges for the different sale batches; F8 and F9 note the option grants and vesting (1,476-share grant vested Feb 14, 2021; 11,345-share grant vested in installments beginning Feb 14, 2017).
• Filing timeliness: Form 4 was filed 2026-02-11 for transactions occurring 2026-02-09/10; no late-filing indication in the report.

Context

• This is a common "exercise + sell" pattern (option exercise followed by immediate open‑market sales). The filing also shows derivative dispositions at $0 for the exercised option lots, which typically reflects shares surrendered/withheld to cover exercise cost or tax obligations (i.e., a sell-to-cover or net share settlement).
• Transaction codes: M = option exercise/conversion; S = open-market sale.
• These actions are factual insider transactions and do not, by themselves, indicate the insider’s broader view of the company.